Di Zhe Pharmaceuticals Reports Revenue Surpassing $500 Million in First Half, Advances Globalization Strategy into Innovation Value Realization Phase
August 20, 2026 — 21:25 CST
This Data Is Locked!
This area is available only to Subscribers.
Di Zhe Pharmaceuticals (stock code: 688192.SH) announced its 2026 interim report on August 20, 2026, revealing a revenue of $523 million during the reporting period,... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
